Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Selvita and Orion have have formed a partnership to jointly develop and commercialise SEL103, Selvita’s proprietary program for the treatment of alzheimer’s disease and other cognitive disorders.
Subscribe to our email newsletter
As per the contract, Selvita is expected to take up responsibility for early research on the program and for the discovery and early preclinical development of small molecules, whereas Orion will take over the pre-clinical and clinical development as well as further commercialization.
Under the terms of the agreement, Selvita will receive upfront and research funding as well as milestone payments from Orion subject to the progress of the development program.
Further, Selvita and Orion are planning to conduct a global research and development program which will combine the resources of Orion’s experienced CNS R&D team with Selvita’s competencies in discovery chemistry and biology assays.
Antti Haapalinna, vice president of research for R&D at Orion, said: The joint program with Selvita is highly in line with our strategy of entering into early stage collaboration with partners having complementary skills to our own activities.”